Checkpoint Inhibitor-TKI Combos Effective in RCC.
Pembrolizumab or avelumab plus axitinib may be effective first-line treatments for clear-cell advanced renal cell carcinoma. In a pair of phase III trials, the checkpoint inhibitor-tyrosine kinase inhibitor combinations extended progression-free survival compared with sunitinib and were associated with relatively manageable side effects.